Aclaris Therapeutics (ACRS) Rating Reiterated by Cantor Fitzgerald

Aclaris Therapeutics (NASDAQ:ACRS)‘s stock had its “buy” rating reissued by stock analysts at Cantor Fitzgerald in a note issued to investors on Friday. They currently have a $50.00 target price on the biotechnology company’s stock.

The analysts wrote, “We expect upwards earnings revisions to levels not reflected in sell-side consensus expectations to drive shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $50.””

A number of other analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday. BidaskClub lowered shares of Aclaris Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, February 23rd. Three equities research analysts have rated the stock with a sell rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $35.94.

Shares of Aclaris Therapeutics stock opened at $5.91 on Friday. Aclaris Therapeutics has a fifty-two week low of $5.49 and a fifty-two week high of $21.97. The company has a market capitalization of $234.15 million, a price-to-earnings ratio of -2.36 and a beta of 1.24.

A number of hedge funds and other institutional investors have recently made changes to their positions in ACRS. Bank of New York Mellon Corp raised its stake in Aclaris Therapeutics by 8.0% during the second quarter. Bank of New York Mellon Corp now owns 423,001 shares of the biotechnology company’s stock worth $8,447,000 after buying an additional 31,339 shares during the last quarter. Russell Investments Group Ltd. raised its stake in Aclaris Therapeutics by 40.3% during the third quarter. Russell Investments Group Ltd. now owns 103,185 shares of the biotechnology company’s stock worth $1,500,000 after buying an additional 29,645 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Aclaris Therapeutics by 2.4% during the third quarter. JPMorgan Chase & Co. now owns 188,380 shares of the biotechnology company’s stock worth $2,735,000 after buying an additional 4,351 shares during the last quarter. BlackRock Inc. raised its stake in Aclaris Therapeutics by 8.9% during the third quarter. BlackRock Inc. now owns 2,517,412 shares of the biotechnology company’s stock worth $36,551,000 after buying an additional 205,771 shares during the last quarter. Finally, Rosenblum Silverman Sutton S F Inc. CA raised its stake in Aclaris Therapeutics by 21.0% during the third quarter. Rosenblum Silverman Sutton S F Inc. CA now owns 89,500 shares of the biotechnology company’s stock worth $1,300,000 after buying an additional 15,515 shares during the last quarter. 95.20% of the stock is owned by institutional investors and hedge funds.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.

Recommended Story: Trading Strategy Methods and Types

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit